drugset / Trial / NCT01252277
Breast Cancer Risk Biomarkers in Premenopausal Women
NaSingle-groupOpen-labelPrevention
Summary
This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer. This drug is currently approved by the FDA for reducing blood levels of triglycerides.
Timeline
- Start
- 2010-11
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lovaza | Other / unclassified | 2 g | — |